
Initiating the cholesterol-lowering drug inclisiran earlier in the treatment pathway leads to significantly better long-term low-density lipoprotein (LDL) reduction compared to usual care in patients with atherosclerotic cardiovascular disease (ASCVD).


coremsg

Results of VICTORION-INITIATE study suggest better results with inclisiran first and highlight "stunning undertreatment" of cholesterol in usual care of patients with CVD.

Earlier Inclisiran Gives Better Long-Term LDL Reductions

initiating-inclisiran-early-leads-to-significantly-better-long-term-ldl-reduction-compared-to-usual-care-in-patients-with-atherosclerotic-cardiovascular-disease


Initiating Inclisiran Early Leads to Significantly Better Long-Term LDL Reduction Compared to Usual Care in Patients with Atherosclerotic Cardiovascular Disease
